Theravance Biopharma (TBPH) Research & Development (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Research & Development data on file, last reported at $5.8 million in Q1 2026.

• On a quarterly basis, Research & Development fell 49.1% year-over-year to $5.8 million in Q1 2026; TTM through Mar 2026 was $31.8 million, a 20.77% decrease from a year earlier, with the FY2025 full-year figure at $37.4 million, down 0.61% from the prior year.
• Research & Development for Q1 2026 stood at $5.8 million, down from $7.4 million in the prior quarter.
• Over the last five years, Research & Development for TBPH reached as high as $23.3 million in Q1 2022 and fell as low as $5.8 million in Q1 2026.
• Historically, Research & Development has averaged $10.9 million across 5 years, with a median of $9.5 million in 2024.
• Across the five-year window, Research & Development sank 77.44% in 2022 and increased 27.7% in 2025, its largest moves.
• Year by year, Research & Development stood at $15.3 million in 2022, then sank by 45.84% to $8.3 million in 2023, then grew by 13.71% to $9.5 million in 2024, then dropped by 22.14% to $7.4 million in 2025, then declined by 20.8% to $5.8 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $5.8 million in Q1 2026, $7.4 million in Q4 2025, and $8.1 million in Q3 2025.